Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LCAR-AIO for the Treatment of Relapsed/Refractory Autoimmune Diseases (r/r AID)

NCT06866080 is registered in ClinicalTrials.gov with Nanjing Legend Biotech Co. as lead sponsor.

NCT NCT06866080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06866080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LCAR-AIO for the Treatment of Relapsed/Refractory Autoimmune Diseases (r/r AID)
Lead sponsor
Nanjing Legend Biotech Co.
Phase
Phase 1
Overall status
Withdrawn
Start date
June 17, 2025
Completion date
June 17, 2025
Enrollment
0 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory autoimmune diseases